Concepedia

Richard Metz

RM

Statistics

Publications

28

Citations

3.7K

H-Index

24

Active since

1977

Affiliations

Lankenau Institute for Medical Research(Current)

NewLink Genetics (United States)

Thomas Jefferson University

Sidney Kimmel Cancer Center

Institute for Biomedical and Pharmaceutical Research

Richard Metz is an author at Lankenau Institute for Medical Research specializing in life sciences, medicine, and immunology.

Publications per year

1977–2019

28

Publications

28

Aryl hydrocarbon receptor control of a disease tolerance defence pathway

Alban Bessede, Marco Gargaro, Maria Teresa Pallotta et al. · Nature · 2014 · 670 citations · Full text

Life Sciences, Molecular Genetics, Cell Signaling +11

Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound <scp>d</scp> -1-Methyl-Tryptophan

Richard Metz, James B. DuHadaway, Uma Kamasani et al. · Cancer Research · 2007 · 463 citations · Full text

Life Sciences, Immunology, Pharmacology +13

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes

Madhav Sharma, De-Yan Hou, Yanjun Liu et al. · Blood · 2009 · 403 citations · Full text

Life Sciences, Immunology, Oncology +14

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Richard Metz, Sonja Rust, James B. DuHadaway et al. · OncoImmunology · 2012 · 377 citations · Full text

Life Sciences, Immunology, Oncology +17

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

Courtney Smith, Mee Young Chang, Katherine H. Parker et al. · Cancer Discovery · 2012 · 324 citations · Full text

Medicine, Oncology, Pathobiology +16

1–5 of 28